Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.
The NOVA trial started a number of years ago, which examines the oral PARP inhibitor, niraparib, explains Matulonis. Patients partaking in the study had to have platinum-sensitive recurrent ovarian cancer and show responsiveness to the platinum-based agent.
This trial was a 2:1 randomization, which enrolled several hundred patients. The results of the study demonstrated an improvement in the median progression-free survival for patients who received niraparib versus placebo.
